

Impact of Hypertension on Type 2 Diabetes in Mysore Population of South India*

Mohammed Salman^{1,2#}, Shruti Dasgupta^{1,3}, Cletus J. M. D'Souza^{1,2}, D. Xaviour¹, B. V. Raviprasad¹, Jayashankar Rao¹, G. L. Lakshmi¹

¹Anthropological Survey of India, Southern Regional Centre, Mysore, India; ²Department of Studies in Biochemistry, University of Mysore, Mysore, India; ³Department of Studies in Biotechnology, University of Mysore, Mysore, India.
Email: #Salman.biochem@gmail.com

Received October 24th, 2013; revised November 20th, 2013; accepted December 5th, 2013

Copyright © 2013 Mohammed Salman *et al.* This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Objective: The study aims to explore the prevalence of hypertension and its impact on Type 2 diabetes in a Mysore population of the Indian subcontinent. **Methods:** 636 participants volunteered for the study. Anthropometric measurements and blood pressure were recorded while plasma was analyzed for biochemical markers. The IDF and JNC 7 diagnostic criteria were followed to define diabetes and hypertension. **Statistical Analyses:** One-way analysis of variance, χ^2 -test and Logistic regression analysis were performed to assess differences of the mean, proportion and the independent effect of hypertension on the development of type 2 diabetes. **Results:** Hypertension was observed to be prevalent in 37.1% of the studied population with an insignificant gender difference. Rate of occurrence of hypertensives was found to be significantly higher in type 2 diabetes (51.9%), obese subjects (45.2%), long-term smokers (49%) and alcohol addicts (48%) than control groups. The risk of development of diabetes was significantly higher in hypertensives than normotensive. However, when creatinine and blood urea nitrogen were included in the model, the significance was nullified. **Conclusions:** The prevalence of type 2 diabetes and hypertension is increasing at an alarming rate. This study reveals that the significance of hypertension as a parameter in predicting the risk of type 2 diabetes was influenced by the renal function and lipid profile.

Keywords: Hypertension; Type 2 Diabetes; Prevalence; Kidney Dysfunction; Mortality; Mysore Population; India

1. Introduction

The incidence of Type 2 Diabetes (T2D) is increasing globally from 2.8% in 2000 to 4.4% in 2030 [1]. The prevalence of T2D in Asian Indians ranges from 2.7% in rural India to 14% in urban India. India has the highest number of diabetes in the world [2,3]. The National Urban Diabetes Survey reported 12.1% of diabetes and 14% of impaired glucose tolerance [4]. The prevalence of hypertension (HTN) among adults is expected to rise by 60% resulting in a total of 1.56 billion affected individuals by 2025. Approximately 70% of diabetics are hypertensives, as diabetics are prone to HTN twice more likely than normoglycemic individuals [5]. Similarly, the presence of HTN precedes the onset of diabetes mellitus (DM) [6,7]; and among diabetics, HTN develops into diabetes

nephropathy and retinopathy. The co-occurrence of HTN and T2D affects up to 60% of patients leading to higher risk of developing cardiovascular morbidity and mortality [8]. Though cardiovascular risks are common in both, in conjunction they accelerate cardiac, cerebral and renal dysfunctions [9]. The United Kingdom Prospective Diabetes Study (UKPDS) revealed that blood pressure control helps to avoid cardiovascular complications in patients with T2D [10]. The decrease in mean systolic blood pressure by 10 mm/Hg reduces the risks of developing complications in diabetes by 12%, mortality by 15%, myocardial infarction by 11% and microvascular complications by 13% among diabetics respectively [11].

The prevalence varies across different ethnic and religious groups in Asia; the co-occurrence of diabetes with HTN shows an increasing trend and has become an epidemic of a great concern [12]. About 50% of diabetes cases in India show the co-occurrence of HTN [13,14].

*Competing Interests: the author(s) declare that they have no competing interests.

#Corresponding author.

Diabetes in other Asian countries such as Saudi Arabia (53%) [15,16], Jordan (72.4%) [17], Oman (21.5%), Turkey (32%), Bahrain (38%) and Taiwan (39%) [18-21] also shows a similar trend. In addition, studies reported higher tendency of HTN among UK Afro-Caribbean (82%) [22], UK Caucasian (74%), Italian (74.4%) and Spanish diabetes (73%) [23-25].

Few epidemiological studies asserting incidence rates of T2D and HTN have been carried out in various sectors of Karnataka. In the rural population of Davanagere, 18.3% of HTN has been reported, where males recorded a higher prevalence rate (19.1%) than females (17.5%) [26]. Heritability of HTN in families of Tumkur population was reported, wherein the young normotensive with a positive family history of HTN had significantly higher blood pressure [27]. In Karnataka, the prevalence of T2D has been observed to be 3.77% of Suttur population [28], 10.0% in Kolar population [29], 16% of the Udupi population [30] and 17.3% in Dharwad urban population [31]. The incidence of obesity among T2D of Mysore population was reported [32], while the awareness of diabetes and their attitude to patients of Bijapur have been reported [33]. But there is no known record of the prevalence of HTN among T2D or vice versa, implying how frequent HTN exacerbates T2D in southern India.

Currently, there are limited epidemiological studies edifying the relationship between T2D and HTN in Indian context. There is an ongoing debate regarding the consideration of high blood pressure over other metabolic components (conjointly involved in T2D and HTN), as a predictor of T2D in Indians. Further, social and cultural diversity in India necessitates the exploration of the mentioned relationship in various sections of this country. Therefore we hypothesize that the risk of incidence of T2D is higher in the subjects with HTN. The present study aims to assess the prevalence of HTN among T2D subjects and its contribution in the occurrence of T2D in Mysore population of Karnataka in South India.

2. Materials and Methods

2.1. Study Population

This case-control study was conducted among participants in the diabetes health check-up programs organized by Amrita Kripa Polyclinic and Lion's Club of Mysore (R) in Mysore district of Karnataka State, India, during 2010 to 2011 including both non-diabetes and diabetes patients, without any mental impairment.

2.2. Sample Size

A total of 654 subjects volunteered and gave consent to participate in the study, out of which 636 were included in the study. The subjects including 343 males and 293 females, aged between 30 - 80 years were enrolled for

the study. Subjects with abnormal renal or chronic liver dysfunction were excluded from the study.

2.3. Sampling Procedure

The study protocol was reviewed and approved by the Institutional Ethics Committee, Kolkata and also the Ethical Committee of University of Mysore. Informed consents were obtained from each participant in the study. The study was conducted according to the ethical guidelines for biomedical research on human populations (http://icmr.nic.in/ethical_guidelines, ICMR 7). Each participant of the study was about 12 hours of fasting period before the collection of blood. 5 ml blood sample was collected in 10 ml BD vacutainer by a phlebotomist, stored at 4°C and transported to the laboratory immediately for further processing. Postprandial plasma glucose was measured after 2 hours of administering 75-grams of glucose to the subjects (OGTT, WHO, 1999).

2.4. Data Collection

Questionnaire: Data was collected on standardized questionnaire that included personal information, lifestyle, habitual behaviors (smoking and alcohol intake), clinical history of associated complications and blood pressure was recorded under the supervision of a physician.

Anthropometry: Height, weight, waist and hip circumference were measured by physical anthropologists using anthropometer (Holtaine, UK) and digital weighing machine (Tanita Corporation, Tokyo, Japan) as per WHO international manual [34]. Waist circumference (WC) was measured at the midpoint at the bottom of the rib cage and the top of the lateral border of the iliac crest during minimal respiration.

Laboratory Examination: Fasting plasma glucose (FPG), Glycated Haemoglobin (HbA1c), High-density lipoprotein (HDL), Low-density lipoprotein (LDL), Total Cholesterol (CHO), Triglycerides (TRIG), Creatinine (CRE), Blood urea nitrogen (BUN) and Postprandial glucose (PPG) were measured on Auto analyzer EM 360 (Transasia, ERBA Mannheim, Germany).

Operational Definitions: Body mass index (BMI) was calculated as weight in kilograms divided by the squared value of height in meters (kg/m^2). BMI was categorized as normal ($<25 \text{ kg}/\text{m}^2$), overweight (>25 and $<30 \text{ kg}/\text{m}^2$), and obese ($>30 \text{ kg}/\text{m}^2$) [35]. Blood pressure (Systolic and Diastolic) of each subject was measured using a standardized sphygmomanometer (Elko, India), in supine position. An average of two readings of both systolic (SBP) and diastolic blood pressure (DBP) was taken. HTN was defined following the criteria of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7

criteria) [36]. Participants were divided (as per their baseline BP) into, normotensive (SBP < 120 mmHg and DBP < 80 mmHg), Pre-hypertensive (SBP 120 - 140 mmHg and DBP 80 - 90 mmHg) and Hypertensive (SBP > 140 mmHg and/ or DBP > 90 mmHg), or presently taking anti-hypertensive medication. Further, hypertensives (presently taking anti-hypertensive medication or/ and with a history of HTN diagnosed by a medical physician) including the pre hypertensive were combined in one group opposed to normotensive controls. Self reported cases and individuals with FPG > 126 mg/dl and PGLU > 200 mg/dl were defined as diabetes [37]. Diabetics under treatment and long term management of blood glucose were defined as controlled diabetes with HbA1c values 6% - 8%. On the contrary above 8% were considered uncontrolled diabetes [38]. All self-reported cases were further validated by medical record review and supplementary questionnaires.

2.5. Statistical Analysis

The analysis has been carried out after segregating the cases and controls further into hypertensives and nor-

motensives, resulting into four groups in total. The results have been reported as mean \pm standard deviation. One-way analysis of variance (ANOVA) was used to analyze the statistical differences in the mean of various parameters between the groups. χ^2 -test was used to compare the proportion of the subjects between different dichotomized variables. Logistic regression analysis was performed to assess the independent effect of hypertensive status on the odds of occurrence of diabetes, after adjusting for confounders. Statistical analyses were performed using SPSS version 12.0 software (SPSS, Chicago, IL, USA). All the reported P-values were two-tailed, and those less than 0.05 were considered statistically significant.

3. Results

Table 1 shows the distribution of HTN across sex, age groups, diabetes status and addiction habits. The overall prevalence rate of HTN was found to be 37.1%, 33.8% of male and 41% in females. However, the intergroup difference is statistically similar ($P > 0.05$). Among different age groups, the rate of HTN increased with age from

Table 1. Distribution of hypertension across age, gender, BMI, habits and clinical history.

Variables	Category	Normotensive		Hypertensive		Total		P value
		N	%	N	%	N	%	
Diabetes status	Type 2 Diabetes	142	48.1	153	51.9	295	100	<0.001
	Non Diabetes	258	75.7	83	24.3	341	100	
Sex	Female	173	59	120	41	293	100	0.63
	Male	227	66.2	116	33.8	343	100	
Age groups	30 - 39	79	86.8	12	13.2	91	100	<0.001
	40 - 49	141	76.2	44	23.8	185	100	
	50 - 59	67	50.8	65	49.2	132	100	
	60 - 69	70	47.6	77	52.4	147	100	
	70 - 79	34	50	34	50	68	100	
BMI groups	80+	9	69.2	4	30.8	13	100	0.009
	Normal (<25)	179	69.6	78	30.4	257	100	
	Overweight (25 - 30)	158	59.8	106	40.2	264	100	
Smoking	Obese (>30)	65	54.8	53	45.2	118	100	0.03
	Yes	76	71.7	30	28.3	106	100	
	No	296	62.3	179	37.7	475	100	
Alcohol intake	Quit	28	50.9	27	49.1	55	100	NS
	Yes	100	67.6	48	32.4	148	100	
	No	287	62	176	38	463	100	
Glycated haemoglobin A1c	Quit	13	52	12	48	25	100	<0.001
	<6%	270	71.8	106	28.2	376	100	
	6% - 8%	87	50.9	84	49.1	171	100	
	>8%	43	48.3	46	51.7	89	100	
Total		400	62.9	236	37.1	636	100	

30 - 69 years and then gradually decreased in subjects of 70 years and above, and the trend was found to be significant ($P < 0.001$). Unconventionally, HTN was significantly less prevalent among smokers than non-smokers whereas long term ex-smokers showed the highest prevalence ($P < 0.05$). A similar trend was observed among alcoholics but was found to be statistically insignificant. Obese subjects were observed to have significantly ($P < 0.01$) higher prevalence rate of HTN (45.2%) than overweight (40.2%) and normal (30.2%) subjects. HTN was found to be more prevalent ($P < 0.001$) among diabetics (51.9%) than non-diabetics (24.3%). This was further substantiated by the significantly ($P < 0.001$) higher prevalence rates among uncontrolled diabetes (51.7%) and controlled diabetes (49.1%) subjects than non-diabetic subjects (28.2%) as categorized by the HbA1c levels.

The variables are described in **Table 2** after classifying the subjects into four groups based on clinical history of diabetes and/or HTN. HTN was more prevalent in subjects of the older age group, irrespective of the presence or absence of T2D. Both diabetes normotensive and hypertensive subjects were observed to have a significantly higher waist circumference than non-diabetic normotensive subjects. Individuals affected by both of the mentioned disorders had higher BMI and CRE levels than normal controls. As anticipated, both systolic and

diastolic blood pressure was higher among hypertensive groups than normotensive. Fasting glucose, postprandial glucose, glycated haemoglobin and triglyceride levels were significantly higher in the diabetes groups, irrespective of HTN. On the contrary, HDL levels were found to be low in the diabetes subjects. Levels of BUN were found to be significantly higher in diabetes hypertensives when compared to diabetes normotensive. CHO and LDL levels showed no significant difference between the groups.

The influence of HTN on risk for development of T2D was analyzed based on HTN status after adjusting the probable cofounder and has been depicted in **Table 3**. The crude odds of occurrence of T2D due to HTN was 3.349 ($P < 0.0001$). Although the odds ratio was reduced after adjusting for the confounders; age, sex, smoking, alcoholism, BMI yet the level of significance was constant. The significance levels were reduced to $P < 0.05$ after the inclusion of FPG, PPG and HbA1c to the previously mentioned models. Though the inclusion of CRE and BUN in the model distorted the significance, but the significance completely disappeared when adjusted for TRIG, CHO, LDL and HDL. When possible confounders were controlled, the odds ratio was found to be 1.45 and was observed to be insignificant. The confounding variables that were found to be significant on inclusion of all variables in the model were Age (OR = 1.053, $P =$

Table 2. Characteristics of the subjects grouped based on presence or absence of diabetes and hypertension.

Biomarker	Diabetic hypertensive	Diabetic normotensive	Nondiabetic hypertensive	Nondiabetic normotensive
	Mean \pm S.D N = 153	Mean \pm S.D N = 142	Mean \pm S.D N = 83	Mean \pm S.D N = 258
Age (years)	59.04 \pm 10.50 [#]	54.26 \pm 12.49*	56.34 \pm 11.65*	48.33 \pm 12.81
Waist (cm)	92.83 \pm 11.45 ^{#^A}	89.98 \pm 12.51*	88.44 \pm 11.18	86.21 \pm 11.05
Body mass index (kg/m) ²	27.37 \pm 4.51 [#]	26.04 \pm 4.25	26.71 \pm 5.18	25.48 \pm 4.55
Systolic blood pressure (mmHg)	152.51 \pm 15.68 [#]	120.86 \pm 12.97 ^A	153.88 \pm 19.25*	110.87 \pm 12.11
Diastolic blood pressure (mmHg)	92.48 \pm 12.13 [#]	82.56 \pm 10.79 ^A	96.07 \pm 11.71*	80.08 \pm 9.93
Fasting glucose (mg/dl)	142.56 \pm 59.19 ^A	145.44 \pm 58.93 ^A	90.20 \pm 11.17	88.45 \pm 9.97
Postprandial glucose (mg/dl)	228.16 \pm 97.34 ^A	228.57 \pm 93.62 ^A	115.71 \pm 24.45	109.39 \pm 22.71
Triglyceride (mg/dl)	184.13 \pm 111.94 ^A	186.65 \pm 105.48 ^A	149.05 \pm 85.89	143.86 \pm 91.58
Cholesterol (mg/dl)	175.18 \pm 45.78	174.06 \pm 51.09	171.78 \pm 49.75	168.58 \pm 47.08
High density lipoprotein (mg/dl)	44.74 \pm 9.95 ^A	47.09 \pm 10.72 ^A	50.49 \pm 7.95	50.08 \pm 8.31
Low density lipoprotein (mg/dl)	101.79 \pm 23.63	102.70 \pm 22.15	100 \pm 21.76	98.05 \pm 20.42
Creatinine (mg/dl)	1.05 \pm 0.49*	0.99 \pm 0.32	0.98 \pm 0.36	0.95 \pm 0.32
Blood urea nitrogen (mg/dl)	10.30 \pm 4.1 [#]	9.12 \pm 3	9.78 \pm 3.24	9.43 \pm 3.32
Glycated haemoglobin A1c (%)	7.45 \pm 2.09 ^A	7.25 \pm 2.13 ^A	5.11 \pm 1.36	4.95 \pm 1.06

* $P < 0.05$ as compared to nondiabetes normotensive. [#] $P < 0.05$ as compared to diabetes normotensive. ^A $P < 0.05$ as compared to nondiabetes hypertensive.

Table 3. Logistic regression analysis for assessing risk of diabetes according to hypertension status.

Models	Odds ratio (Hypertensive vs. normotensive)	CI interval	P value
1	3.349	2.392 - 4.690	<0.0001
2	2.940	2.057 - 4.203	<0.0001
3	2.953	2.058 - 4.236	<0.0001
4	2.589	1.789 - 3.746	<0.0001
5	2.220	1.225 - 4.024	0.009
6	1.862	1.007 - 3.444	0.048
7	1.830	0.984 - 3.403	0.056
8	1.431	0.723 - 2.831	0.303
9	1.452	0.732 - 2.881	0.286

Model 1: Unadjusted. Model 2: Adjusted for Age and gender. Model 3: Adjusted for model 2 + smoking + Alcoholism. Model 4: Adjusted for model 3 + BMI. Model 5: Adjusted for model 3 + FPG + PPG + HbA1c. Model 6: Adjusted for model 5 + BMI. Model 7: Adjusted for model 6 + CRE + BUN. Model 8: Adjusted for model 6 + TRIG + HDLC + LDLC + CHO. Model 9: Adjusted for model 8 + CRE + BUN.

0.001), FPG (OR = 1.06, $P < 0.0001$) PGLU (OR = 1.043, $P < 0.0001$), HbA1c (OR = 1.06, $P < 0.0001$), BMI (OR = 1.099, $P < 0.01$), HDLC (OR = 0.863, $P < 0.0001$) and LDLC (OR = 1.033, $P < 0.004$).

4. Discussion

Several studies have reported the prevalence of HTN and T2D in rural as well as urban India. However, studies linking HTN to T2D in India are minimal. According to Screening India's Twin Epidemic (SITE) study, the prevalence rate of the co-occurrence of HTN and T2D in individual of eight states was 20.6%, with 34.7% of T2D and 46% of HTN. In Karnataka, the frequency of co-occurrence of HTN and T2D is 17.4%, whereas HTN and T2D occur alone at 32.1% and 34.5% respectively [39]. In the present study, co-occurrence of HTN and T2D was observed to be 24.1% of the Mysore population with a higher prevalence rate of HTN (37.1%) and T2D (46.4%) than reported by SITE study for the entire Karnataka population. Our study shows a higher rate of incidence of these disorders within Karnataka, more specifically in populations of Mysore district. The incidence of HTN among T2D patients in the present study population (51.9%) is comparable to T2D incidence in Kashmir (42%) and varies from other populations of India [13-25]. The differences observed in the incidences of HTN in T2D among different populations can possibly be attributed to ethnicity, population dispersion, physical characteristics and the multiple definitions adopted for T2D/HTN and surveillance procedures in the previous studies.

Studies on the glycemic control stages marked by HbA1c levels are limited in various populations. Studies have shown that intensive blood sugar control is effective in reducing the risk of HTN by approximately 25%. Our

findings are in conformity with earlier studies, where the incidence of HTN among T2D subjects having glycemic control (HbA1c < 8%) is lower than in uncontrolled group (HbA1c > 8%) [40,41]. Customarily, hypertensivity in diabetes advances with age as reported in other studies [42-45]. Contrastingly, we observed a lag in the occurrence of HTN in subjects beyond the age of 70 years, which can be attributed to the lower levels of BMI. In accordance with earlier findings higher BMI group showed a high prevalence rate for HTN [44-46]. Further, high prevalence of HTN among ex-smokers projects the probable association of the disorder with the duration of addictive behaviors. An unusual trend has been reported in prior studies of higher prevalence of hypertensives amongst former smokers and non smokers than smokers which harmonize with our results [47,48]. The possible answer could be the unwillingness of individuals to disclose their addictive behavior and also occurrence of obese/overweight subjects under the smokers' category.

It has been established that co-existence of T2D and HTN accelerates the progression of metabolic abnormalities more than their independent outcomes. Hence, there is always a chance of significant variability in metabolic characteristics between individuals suffering independently with both disorders or with the coexistence [49]. In our study the population is categorized into four groups (Non diabetes normotensive, Non diabetes hypertensive, diabetes normotensive and diabetes hypertensive) referring to four conditions, with significant observed differences among the groups. Insulin resistance in T2D causes inhibition of lipolysis leading to hyperinsulinemia and elevated triglyceride [50]. Our findings are in agreement with the aforesaid inference, wherein elevated levels of fasting glucose, postprandial glucose, glycated

haemoglobin, triglyceride levels of FPG, PPG, HbA1c, TRIG and low levels of HDL levels were observed in diabetes hypertensives and normotensive groups. Our finding is in concordance with earlier studies, suggesting the association of T2D with dyslipidemia, particularly with high triglycerides accompanied with a simultaneous decrease in HDL cholesterol [51]. Positive association between HTN and abnormal lipid profiles in rural population of Bagalkot in Karnataka [52] and among hospital patients have been reported in previous studies on Indian population [53,54].

Elevated BUN has been reported to be a marker for activating the sympathetic nervous system and an unregulated rennin angiotensin system. Thus increased levels of BUN in T2D with HTN distinctly reveals the risk of renal and atherosclerotic complications in diabetes hypertensives than diabetes normotensive [55-59]. In the present study, the co-incidence of T2D and HTN as defined by higher BMI and CRE levels strengthens the notion that obesity and renal dysfunction are predictors of T2D associated with HTN.

Our study indicates that HTN plays a major role in the development of T2D, after the confounding effects of age, sex, BMI, glycemic index (FPG, PPG and HbA1c), lipid profile, CRE and other relevant factors had been adjusted. Our result concurs with the recent findings that aging, obesity, dysglycaemia and dyslipidemia co-exist with HTN and T2D [17,60,61]. Studies reported a precise and prominent role of HTN in the prevalence of T2D with crude relative risks of 2.34 (CI of 2.16 - 2.73) [62] and 2.65 (CI of 1.88 - 3.73) [63], relatively lower than the ratio obtained in our study. This evidently suggests that Mysore population is at a higher risk of T2D due to HTN. Previous studies on Asian populations proposed that baseline hyperglycemia and BMI are potential covariates determining the association of HTN with T2D. Thus, baseline HTN may be a potential predictor for incident diabetes, if the onset of diabetes is defined using parameters like FPG and PPG levels [61]. However, it has been concluded that obesity and metabolic syndrome does not explain the entire association between BP and incidence of T2D [63]. Hence, besides BMI, lipid profile and Glycemic index, we included CRE and BUN into these models. Accumulation of BUN and CRE is a direct indicator of renal dysfunction. Thus higher levels of these are observed in hypertensives, more precisely in untreated hypertensives and diabetes nephropathy cases [64]. Furthermore, it has been reported that renal failure rate is two to three times higher in patients of diabetes hypertensives than in non diabetes hypertensives [65]. Therefore, inclusion of these predictors can ascertain the association between T2D and HTN. Lack of correction for the predictor variables related to renal dysfunction can be one of the reasons for discrepancies in the earlier

studies [61,62].

5. Limitations and Strengths

This study is the first of its kind in South Indian population. Glycemic index is defined more explicitly in this study by performing OGTT and HbA1c estimations compared to earlier studies, which failed to include glucose tolerance [62,66]. Some of the major limitations of this study are complete exclusion of the effects of residual confounding due to measurement errors, *i.e.* in the assessment of confounding factors or unmeasured dietary, social and economic factors. Data could not be stratified gender wise because of small sample size. The sample population was heterogeneous consisting of both urban and rural inhabitants, thus findings cannot be generalized to other populations of India. Although clinical data are available, duration and history of diabetes and HTN was not taken into consideration for the study. Some of the salient markers like micro albumin, urea and insulin are beyond the scope of this paper. Non availability of information regarding the treatment for HTN in subjects of the hypertensive group, to see the effect of treatment of diabetes, was one of the lacunae.

6. Conclusion

The high prevalence rate of T2D and HTN is major concerns in Mysore population. HTN plays a key role in the progression of T2D and is associated with vascular complications. Among hypertensives, BMI, Glycemic index, lipid profile and kidney dysfunction, markers are potential predictors of T2D. The assessment of nephropathic markers besides analyzing metabolic components and blood pressure management is better approaches to prevent the risk of development of T2D in hypertensives.

7. Authors' Contributions

MDS conceived and executed the study. SDG helped in sample collection, laboratory work and statistical analysis. CDS supervised the research, proof read the draft. DDX, BVR, JSR and LGL contributed in formulation of data collection. All authors read and approved the final manuscript.

8. Acknowledgements

The authors express gratitude to the Director, Anthropological Survey of India, Ministry of Culture, Government of India, Kolkata for sponsoring the project. We express thanks to Deputy Director and staff of the Anthropological Survey of India for extending technical and administrative support. We are grateful to all the participants of the study. We are indebted to the Lions Club of Mysore, Drs. Vikas Modi, Pushpa Jogihalli and Ramakrishna of

Amritakripa Hospital, Rupanagar, Mysore for holding medical camps in Mysore. We appreciate the assistance provided by the paramedical staff in the collection of blood samples. Thanks are also due to Abrar Alam, Ranjith, Pratiksha Bhat, Amith, Suprabha Samanta, Deepti Lokanath, and Sanjukta Mukherjee for their cooperation.

REFERENCES

- [1] G. S. Wild, G. Roglic, A. Green, R. Sicree and H. King, "Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030," *Diabetes Care*, Vol. 27, No. 5, 2004, pp. 1047-1053. <http://dx.doi.org/10.2337/diacare.27.5.1047>
- [2] B. Basnayar and L. Rajapasha, "Cardiovascular and Infectious Diseases in South Asia: The Double Whammy," *British Medical Journals*, Vol. 328, No. 7443, 2004, p. 781. <http://dx.doi.org/10.1136/bmj.328.7443.781>
- [3] D. Yach, C. Hawkes, C. L. Gould and K. J. Hofman, "The Global Burden of Chronic Diseases: Overcoming Impediments to Prevention and Control," *Journal of the American Medical Association*, Vol. 291, No. 21, 2004, pp. 2616-2622. <http://dx.doi.org/10.1001/jama.291.21.2616>
- [4] A. Ramachandran, C. Snehalatha, A. Kapur, V. Vijay, V. Mohan, A. K Das, P. V. Rao, C. S. Yajnik, K. M. Prassanna Kumar and J. D. Nair, "Diabetes Epidemiology Study Group in India (DESI): High Prevalence of Diabetes and Impaired Glucose Tolerance in India: National Urban Diabetes Survey," *Diabetologia*, Vol. 44, No. 9, 2001, pp. 1094-1101. <http://dx.doi.org/10.1007/s001250100627>
- [5] R. Klein, B. E. Klein, K. E. Lee, K. J. Cruickshanks and S. E. Moss, "The Incidence of Hypertension in Insulin Dependent Diabetes," *Archives of Internal Medicine*, Vol. 156, No. 6, 1996, pp. 622-627. <http://dx.doi.org/10.1001/archinte.1996.00440060042005>
- [6] D. Conen, P. M. Ridker, S. Mora, J. E. Buring and R. J. Glynn, "Blood Pressure and Risk of Developing Type 2 Diabetes Mellitus: The Womens Health Study," *European Heart Journal*, Vol. 28, No. 23, 2007, pp. 2937-2943. <http://dx.doi.org/10.1093/eurheartj/ehm400>
- [7] P. W. Wilson, J. B. Meigs, L. Sullivan, C. S. Fox and D. M. Nathan and R. B. D'Agostino Sr, "Prediction of Incident Diabetes Mellitus in Middle-Aged Adults: The Framingham Offspring Study," *Archives of Internal Medicine*, Vol. 167, No. 10, 2007, pp. 1068-1074. <http://dx.doi.org/10.1001/archinte.167.10.1068>
- [8] R. E. Aubert, L.S. Geiss, D. J. Ballard, B. Cocanougher and W. H. Herman, "Diabetes-Related Hospitalization and Hospital Utilization," In: *Diabetes in America*, 2nd Edition, National Diabetes Information Clearinghouse, 1 Information Way, Bethesda, 1995, pp. 553-569.
- [9] N. M. Kaplan and E. Lieberman, "Hypertension and Diabetes, Obesity, and Dyslipidaemia in Clinical Hypertension," 7th Edition, New Delhi, B.I. Waverly Pvt. Ltd, 1998, pp. 244-247.
- [10] UK Prospective Diabetes Study (UKPDS) Group, "Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39," *British Medical Journals*, Vol. 317, No. 7175, 1998, pp. 703-713.
- [11] UK Prospective Diabetes Study (UKPDS) Group, "Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39," *British Medical Journals*, Vol. 317, No. 7160, 1998, pp. 713-720. <http://dx.doi.org/10.1136/bmj.317.7160.713>
- [12] A. Ramachandran, R. C. Ma and C. Snehalatha, "Diabetes in Asia," *Lancet*, Vol. 375, No. 9712, 2010, pp. 408-418. [http://dx.doi.org/10.1016/S0140-6736\(09\)60937-5](http://dx.doi.org/10.1016/S0140-6736(09)60937-5)
- [13] R. B. Singh, R. Beegom and V. Rastogi, "Clinical Characteristics and Hypertension among Known Patients of Non-Insulin Dependent Diabetes Mellitus in North and South Indians," *Journal of the Diabetic Association of India*, Vol. 36, 1996, pp. 45-50.
- [14] S. Jain and J. C. Patel, "Diabetes and Hypertension," *Journal of the Diabetic Association of India*, Vol. 23, 1983, pp. 83-86.
- [15] G. N. Dhobi, A. Majid, S. R. Masoodi, M. I. Bashir, A. I. Wani and A. H. Zargar, "Prevalence of Hypertension in Patients with New Onset Type 2 Diabetes Mellitus," *Journal of the Indian Medical Association*, Vol. 106, No. 2, 2008, pp. 94-98.
- [16] D. Akbar, M. M. Ahmed and A. A. Algamdi, "Cardiovascular Risk Factors in Saudi and Non-Saudi Diabetics," *Saudi Medical Journal*, Vol. 24, No. 6, 2003, pp. 686-687.
- [17] F. M. Mubarak, S. F. Erika, Y. J. Hashem and M. A. Kamel, "Hypertension among 1000 Patients with Type 2 Diabetes Attending a National Diabetes Center in Jordan," *Annals of Saudi Medicine*, Vol. 28, No. 5, 2008, pp. 346-351. <http://dx.doi.org/10.4103/0256-4947.51684>
- [18] S. Al-Moosa, S. Allin, N. Jemiai, J. Al-Lawati and E. Mossialos, "Diabetes and Urbanization in the Omani Population: An Analysis of National Survey Data," *Population Health Metrics*, Vol. 24, No. 1, 2006, pp. 1-8.
- [19] I. Satman, T. Yilmaz, A. Sengül, S. Salman, F. Salman, S. Uygur, I. Bastar, Y. Tütüncü, M. Sargin, N. Dinççag, K. Karsidag, S. Kalaça, C. Ozcan and H. King, "Population-Based Study of Diabetes and Risk Characteristics in Turkey," *Diabetes Care*, Vol. 25, No. 9, 2002, pp. 1551-1556. <http://dx.doi.org/10.2337/diacare.25.9.1551>
- [20] F. Al-Mahroos, K. Al-Roomi and P. M. McKeigue, "Relation of High Blood Pressure to Glucose Intolerance, Plasma Lipids and Educational Status in an Arabian Gulf Population," *International Journal of Epidemiology*, Vol. 29, No. 1, 2000, pp. 71-76. <http://dx.doi.org/10.1093/ije/29.1.71>
- [21] C. H. Tseng, "Higher Risk of Hypertension in Indigenous Type 2 Diabetic Patients in Taiwan," *Journal of Hypertension*, Vol. 24, No. 9, 2006, pp. 1817-1821. <http://dx.doi.org/10.1097/01.hjh.0000242406.76085.c4>
- [22] V. Baskar, D. Kamalakannan, M. R. Holland and B. M. Singh, "Does Ethnic Origin Have an Independent Impact on Hypertension and Diabetic Complications?" *Diabetes, Obesity and Metabolism*, Vol. 8, No. 2, 2006, pp. 214-219. <http://dx.doi.org/10.1111/j.1463-1326.2005.00485.x>

- [23] V. Baskar, D. Kamalakannan, M. R. Holland and B. M. Singh, "The Prevalence of Hypertension and Utilization of Antihypertensive Therapy in a District Diabetes Population," *Diabetes Care*, Vol. 25, No. 11, 2002, pp. 2107-2108. <http://dx.doi.org/10.2337/diacare.25.11.2107>
- [24] M. Comaschi, C. Coscelli, D. Cucinotta, P. Malini, E. Manzato and A. Nicolucci, "Cardiovascular Risk Factors and Metabolic Control in Type 2 Diabetic Subjects Attending Outpatient Clinics in Italy: The SFIDA (Survey of Risk Factors in Italian Diabetic Subjects by AMD) Study," *Nutrition, Metabolism and Cardiovascular Diseases*, Vol. 15, No. 3, 2005, pp. 204-211. <http://dx.doi.org/10.1016/j.numecd.2004.07.003>
- [25] F. J. Del Cañizo-Gómez and M. N. Moreira-Andrés, "Cardiovascular Risk Factors in Patients with Type 2 Diabetes. Do We Follow the Guidelines?" *Diabetes Research and Clinical Practice*, Vol. 65, No 2, 2004, pp. 125-133. <http://dx.doi.org/10.1016/j.diabres.2003.12.002>
- [26] B. Y. Yuvraj, M. R. Nagendragowda and A. G. Umakantha, "Prevalence, Awareness, Treatment and Control of Hypertension in Rural Areas of Davanagere," *Indian Journal of Community Medicine*, Vol. 35, No. 1, 2010, pp. 138-241. <http://dx.doi.org/10.4103/0970-0218.62578>
- [27] G. Dayananda and M. Niranjana, "Blood Pressure Changes in Normotensive Subjects with and without Family History of Hypertension," *Journal of Physiology and Biomedical Sciences*, Vol. 22, No. 1, 2009, pp. 35-37.
- [28] H. Basavanagowdappa, A. K. Prabhakar, P. Prasannaraj, K. C. Gurudev, Virupaksha and Suma, "Study of Prevalence of Diabetes Mellitus and Impaired Fasting Glucose in a Rural Population," *International Journal of Diabetes Developing Countries*, Vol. 25, No. 4, 2005, pp. 98-101. <http://dx.doi.org/10.4103/0973-3930.27012>
- [29] C. Muninarayana, G. Balachandra, S. G. Hiremath, I. Krishna and N. S. Anil, "Prevalence and Awareness Regarding Diabetes Mellitus in Rural Tamaka, Kolar," *International Journal of Diabetes Developing Countries*, Vol. 30, No. 1, 2010, pp. 18-31.
- [30] C. R. Rao, V. G. Kamath, A. Shetty and A. Kamath, "A Study on the Prevalence of Type 2 Diabetes in Coastal Karnataka," *International Journal of Diabetes Developing Countries*, Vol. 30, No. 2, 2010, pp. 80-85.
- [31] S. Pushpa Patil, R. Umesh Dixit and B. H. Dhruvkumar, "Study of Diabetes in Dharwad—An Urban Area in India," *Indian Journal of Science and Technology*, Vol. 4, No. 11, 2011, pp. 1481-1483.
- [32] M. A. Shekar, H. M. Somashekar and B. S. Vishwanath, "Study of Incidence of Obesity in Newly Diagnosed Type 2 Diabetics Using Anthropometric Measurements," *International Journal of Diabetes Developing Countries*, Vol. 25, No. 4, 2005, pp. 102-104.
- [33] C. K. Priyankaraj and M. M. Angadi, "Hospital-Based KAP Study on Diabetes in Bijapur, Karnataka," *Indian Journal of Medical Specialities*, Vol. 1, No. 2, 2010, pp. 80-83.
- [34] World Health Organization, "Physical Status: The Use and Interpretation of Anthropometry. Report of the WHO Expert Committee," *World Health Organization Technical Report Series*, Vol. 854, Geneva, 1995, pp. 1-416.
- [35] World Health Organization, "Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation," *World Health Organization Technical Report Series*, Vol. 894, 2000, pp. 1-253.
- [36] A. V. Chobanian, G. L. Bakris, H. R. Black, W. C.ushman, L. A. Green, J. L. Izzo Jr., D. W. Jones, B. J. Materson, S. Oparil, J. T. Wright Jr. and E. J. Roccella, "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report," *Journal of the American Medical Association*, Vol. 289, No. 19, 2003, pp. 2560-2572. <http://dx.doi.org/10.1001/jama.289.19.2560>
- [37] K. G. Alberti and P. Z. Zimmet, "Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus Provisional Report of a WHO Consultation," *Diabetic Medicine*, Vol. 15, No. 7, 1998, pp. 539-553. [http://dx.doi.org/10.1002/\(SICI\)1096-9136\(199807\)15:7<539::AID-DIA668>3.0.CO;2-S](http://dx.doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S)
- [38] D. M. Nathan, D. E. Singer, K. Hurxthal and J. D. Goodson, "The Clinical Information Value of the Glycosylated Hemoglobin Assay," *New England Journal of Medicine*, Vol. 310, No. 6, 1984, pp. 341-346. <http://dx.doi.org/10.1056/NEJM198402093100602>
- [39] S. R. Joshi, B. Saboo, M. Vadivale, S. I. Dani, A. Mithal, U. Kaul, M. Badgandi, S. S. Iyengar, V. Viswanathan, N. Sivakadaksham, P. S. Chattopadhyaya, A. D. Biswas, S. Jindal, I. A. Khan, B. K. Sethi, V. D. Rao and J. J. Dalal, "SITE Investigators Prevalence of Diagnosed and Undiagnosed Diabetes and Hypertension in India Results from the Screening India's Twin Epidemic (SITE) Study," *Diabetes Technology and Therapeutics*, Vol. 14, No. 1, 2012, pp. 8-15. <http://dx.doi.org/10.1089/dia.2011.0243>
- [40] I. H. de Boer, B. Kestenbaum, T. C. Rue, M. W. Steffes, P. A. Cleary, M. E. Molitch, J. M. Lachin, N. S. Weiss and J. D. Brunzell, "Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus," *Archives of Internal Medicine*, Vol. 168, No. 17, 2008, pp. 1867-1873. <http://dx.doi.org/10.1001/archinternmed.2008.2>
- [41] Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, "Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic Nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study," *Journal of the American Medical Association*, Vol. 290, No. 16, 2003, pp. 2159-2167. <http://dx.doi.org/10.1001/jama.290.16.2159>
- [42] T. M. Davis, I. M. Stratton, C. J. Fox, R. R. Holman and R. C. Turner, "UK Prospective Diabetes Study 22. Effect of Age at Diagnosis on Diabetic Tissue Damage during the First 6 Years of NIDDM," *Diabetes Care*, Vol. 40, No. 9, 1997, pp. 1435-1441. <http://dx.doi.org/10.2337/diacare.20.9.1435>
- [43] C. C. Cowie and M. I. Harris, "Physical and metabolic characteristics of persons with diabetes," In: M. I. Harris, Ed., *Diabetes in America*, 2nd edition, National Diabetes Information Clearinghouse, 1 Information Way, Bethesda, 1995, pp. 117-164.
- [44] J. M. Sprafka, A. P. Bender and H. G. Jagger, "Preva-

- lence of Hypertension and Associated Risk Factors among Diabetic Individuals: The Three-City Study," *Diabetes Care*, Vol. 11, No. 1, 1988, pp. 17-22. <http://dx.doi.org/10.2337/diacare.11.1.17>
- [45] "Hypertension in Diabetic Study (HDS): 1. Prevalence of Hypertension in Newly Presenting Type 2 Diabetic Patients and the Association with Risk Factors for Cardiovascular and Diabetic Complications," *Journal of Hypertension*, Vol. 11, No. 3, 1993 pp. 309-317. <http://dx.doi.org/10.1097/00004872-199303000-00012>
- [46] T. A. Hillier and K. L. Pedula, "Characteristics of an Adult Population with Newly Diagnosed Type 2 DM: The Relation of Obesity and Age of Onset," *Diabetes Care*, Vol. 24, No. 9, 2001, pp. 1522-1527. <http://dx.doi.org/10.2337/diacare.24.9.1522>
- [47] S. G. Manfred, J. Eliezer and L. Yair, "Blood Pressure in Smokers and Nonsmokers: Epidemiologic Findings," *American Heart Journal*, Vol. 111, No. 5, 1986, pp. 932-940. [http://dx.doi.org/10.1016/0002-8703\(86\)90645-9](http://dx.doi.org/10.1016/0002-8703(86)90645-9)
- [48] L. Duk-Hee, H. Myung-Hwa, K. Jang-Rak and R. J. David, "Effects of Smoking Cessation on Changes in Blood Pressure and Incidence of Hypertension A 4-Year Follow-Up Study," *Hypertension*, Vol. 37, No. 2, 2001, pp. 194-198. <http://dx.doi.org/10.1161/01.HYP.37.2.194>
- [49] W. O. Balogun and B. L. Salako, "Co-Occurrence of Diabetes and Hypertension: Pattern and Factors Associated with Order of Diagnosis among Nigerians," *Annals of Ibadan Postgraduate Medicine*, Vol. 9, No. 2, 2011, pp. 89-93.
- [50] J. M. Brun, "What Is the Purpose to Assess Triglyceridemia during Treatment of NIDDM?" *Diabetes and Metabolism*, Vol. 23, No. 3, 1997, pp. 258-263.
- [51] G. M. Reaven, H. Lithell and L. Landsberg, "Hypertension and Associated Metabolic Abnormalities—The Role of Insulin Resistance and the Sympathoadrenal System," *New England Journal of Medicine*, Vol. 334, No. 6, 1996, pp. 374-381. <http://dx.doi.org/10.1056/NEJM199602083340607>
- [52] R. Pramila Devi, S. M. Gooranavar, S. B. Biradar, M. C. Baragundi, S. A. Kora and M. Narayan, "Study of Lipid Profile in Hypertensive Patients in Rural Karnataka," *Journal of Pharmaceutical And Biomedical Sciences*, Vol. 7, No. 18, 2011, pp. 1-6.
- [53] S. J. Jogalekar, "Co-Existence of Hypertension and Abnormal Lipid Profile, a Hospital Based Retrospective Survey," *Indian Heart Journal*, Vol. 49, No. 3, 1997, pp. 275-278.
- [54] A. S. Hakim, S. A. Kamath and Mamata, "A Retrospective Study of Lipid Profile in 500 Hypertensive Patients," *Journal of the Association of Physicians of India*, Vol. 45, No. 12, 1997, pp. 943-944.
- [55] A. J. Kirtane, D. M. Leder, S. S. Waikar, G. M. Chertow, K. K. Ray, D. S. Pinto, D. Karpaliotis, A. J. Burger, S. A. Murphy, C. P. Cannon, E. Braunwald and C. M. Gibson, "Serum Blood Urea Nitrogen as an Independent Marker of Subsequent Mortality among Patients with Acute Coronary Syndromes and Normal to Mildly Reduced Glomerular Filtration Rates," *Journal of the American College of Cardiology*, Vol. 45, No. 11, 2005, pp. 1781-1786. <http://dx.doi.org/10.1016/j.jacc.2005.02.068>
- [56] R. Ostfeld, D. Mookherjee, M. Spinelli, D. Holtzman, A. Shoyeb, M. Schaefer, S. Doddamani, D. Spevack and Y. Du, "A Triglyceride/High-Density Lipoprotein Ratio $>or = 3.5$ Is Associated with an Increased Burden of Coronary Artery Disease on Cardiac Catheterization," *Journal of the Cardiometabolic Syndrome*, Vol. 1, No. 1, 2006, pp. 13-15. <http://dx.doi.org/10.1111/j.0197-3118.2006.05323.x>
- [57] P. E. Tummala, X. L. Chen, C. L. Sundell, J. B. Laursen, P. Hammes, R. W. Alexander, D. G. Harrison and R. M. Medford, "Angiotensin II Induces Vascular Cell Adhesion Molecule-1 Expression in Rat Vasculature," *Circulation*, Vol. 100, No. 11, 1999, pp. 1223-1229. <http://dx.doi.org/10.1161/01.CIR.100.11.1223>
- [58] S. B. Manuck, J. R. Kaplan, M. R. Adams and T. B. Clarkson, "Effects of Stress and the Sympathetic Nervous System on Coronary Atherosclerosis in the Cynomolgus Macaque," *American Heart Journal*, Vol. 116, No. 1, 1988, pp. 328-333. [http://dx.doi.org/10.1016/0002-8703\(88\)90110-X](http://dx.doi.org/10.1016/0002-8703(88)90110-X)
- [59] A. Rozanski, J. A. Blumenthal and J. Kaplan, "Impact of Psychological Factors on the Pathogenesis of Cardiovascular Disease and Implications for Therapy," *Circulation*, Vol. 99, 1999, pp. 2192-2217. <http://dx.doi.org/10.1161/01.CIR.99.16.2192>
- [60] V. S. Joe, P. Tiffany, J. K. Andrew, A. Mark, S. Stephen, L. Jean, A. Arnold and D. Pettitt, "High Rates of Co-Occurrence of Hypertension, Elevated Low-Density Lipoprotein Cholesterol, and Diabetes Mellitus in a Large Managed Care Population," *American Journal of Managed Care*, Vol. 10, No. 2, 2004, pp. 163-170.
- [61] Y. L. Won, H. K. Chang, J. R. Eun, B. P. Jeong, K. K. Young and Y. W. Sook, S. Kim and K. C. Sung, "The Effect of Body Mass Index and Fasting Glucose on the Relationship between Blood Pressure and Incident Diabetes Mellitus: A 5-Year Follow-Up Study," *Hypertension Research*, Vol. 34, No. 10, 2011, pp. 1093-1097. <http://dx.doi.org/10.1038/hr.2011.89>
- [62] T. W. Gress, F. J. Nieto, E. Shahar, M. R. Wofford and F. L. Brancati, "Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus. Atherosclerosis Risk in Communities Study," *New England Journal of Medicine*, Vol. 342, No. 13, 2000, pp. 905-912. <http://dx.doi.org/10.1056/NEJM200003303421301>
- [63] C. David, M. R. Paul, M. Samia, E. B. Julie and J. G. Robert, "Blood Pressure and Risk of Developing Type 2 Diabetes Mellitus: The Women's Health Study," *European Heart Journal*, Vol. 28, No. 23, 2007, pp. 2937-2943. <http://dx.doi.org/10.1093/eurheartj/ehm400>
- [64] C. Josef, W. G. Laura, M. Geraldine, L. B. Fredrick, S. L. Andrew, J. Camille and J. K. Michael, "Prevalence of High Blood Pressure and Elevated Serum Creatinine Level in the United States," *Archives of Internal Medicine*, Vol. 161, No. 9, 2001, pp. 1207-1216. <http://dx.doi.org/10.1001/archinte.161.9.1207>
- [65] "Hypertension in Diabetic Study (HDS), II. Increased Risk of Cardiovascular Complications in Hypertensive Type 2 Diabetic Patients," *Journal of Hypertension*, Vol.

11, No. 3, 1993, pp. 319-325.

<http://dx.doi.org/10.1097/00004872-199303000-00013>

- [66] G. Hu, J. Pekka and T. Jaakko, "Joint Effects of History of Hypertension at Baseline and Type 2 Diabetes at Base-

line and during Follow-Up on the Risk of Coronary Heart disease," *European Heart Journal*, Vol. 28, No. 24, 2007, pp. 3059-3066.

<http://dx.doi.org/10.1093/eurheartj/ehm501>